Jean L. Rouleau
YOU?
Author Swipe
View article: Assessing vulnerability to energy poverty through occupant-centric building simulations
Assessing vulnerability to energy poverty through occupant-centric building simulations Open
View article: How Does Energy Transition Impact Vulnerable Populations? A Review of Challenges, Determinants, and Solutions for a Just Transition
How Does Energy Transition Impact Vulnerable Populations? A Review of Challenges, Determinants, and Solutions for a Just Transition Open
The concepts of energy justice, energy poverty, and energy equity have gained considerable recognition over the past decade. It is now understood that energy transition processes and activities, despite evident benefits, can lead to injust…
View article: Analyzing and improving the thermal performance of road network weighing stations through measurements and CFD modeling
Analyzing and improving the thermal performance of road network weighing stations through measurements and CFD modeling Open
Weighing stations ensure the safety and durability of road infrastructures. In cold climates, weighing stations are heated to melt accumulated snow and maintain an adequate operating temperature, resulting in significant energy consumption…
View article: Oxygen supplementation in ambulatory patients with heart failure: a randomized proof-of-concept study
Oxygen supplementation in ambulatory patients with heart failure: a randomized proof-of-concept study Open
Aims The aims of this study were to describe the short-term effects of oxygen therapy on the physiological response and symptoms during ambulation in patients with chronic heart failure (HF). Methods and results In this pilot, cross-over, …
View article: Sustainable Heating Analysis and Energy Model Development of a Community Building in Kuujjuaq, Nunavik
Sustainable Heating Analysis and Energy Model Development of a Community Building in Kuujjuaq, Nunavik Open
Energy transition is a challenge for remote northern communities mainly relying on diesel for electricity generation and space heating. Solar-assisted ground-coupled heat pump (SAGCHP) systems represent an alternative that was investigated…
View article: Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF Open
View article: Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis
Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis Open
Background and Aims In the Surgical Treatment for Ischaemic Heart Failure Trial Extension Study (STICHES), coronary artery bypass grafting (CABG) improved outcomes of patients with ischaemic left ventricular dysfunction receiving medical t…
View article: Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial
Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial Open
Background and Aims An expansion of fat mass is an integral feature of patients with heart failure and preserved ejection fraction (HFpEF). While body mass index (BMI) is the most common anthropometric measure, a measure of central adiposi…
View article: Assessing Vulnerability to Energy Poverty Through Occupant-Centric Building Simulations
Assessing Vulnerability to Energy Poverty Through Occupant-Centric Building Simulations Open
View article: Mortality after high‐risk myocardial infarction over the last 20 years: Insights from the <scp>VALIANT</scp> and <scp>PARADISE</scp>‐<scp>MI</scp> trials
Mortality after high‐risk myocardial infarction over the last 20 years: Insights from the <span>VALIANT</span> and <span>PARADISE</span>‐<span>MI</span> trials Open
Aims The temporal changes in clinical profiles and outcomes of high‐risk myocardial infarction survivors enrolled in clinical trials are poorly described. This study compares mortality rates, baseline characteristics, and the prognostic im…
View article: Visit‐to‐visit changes in heart rate in heart failure: A pooled participant‐level analysis of the <scp>PARADIGM</scp>‐<scp>HF</scp> and <scp>PARAGON</scp>‐<scp>HF</scp> trials
Visit‐to‐visit changes in heart rate in heart failure: A pooled participant‐level analysis of the <span>PARADIGM</span>‐<span>HF</span> and <span>PARAGON</span>‐<span>HF</span> trials Open
Aims Resting heart rate (HR) is a strong risk marker in patients with heart failure (HF), but the clinical implications of visit‐to‐visit changes in HR (ΔHR) are less well established. We aimed to explore the association between ΔHR and su…
View article: Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction Open
Aims In the absence of randomized trial evidence, we performed a large observational analysis of the association between beta‐blocker (BB) use and clinical outcomes in patients with heart failure (HF) and mildly reduced (HFmrEF) and preser…
View article: Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure Open
Importance Sacubitril/valsartan is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalizations in patients with chronic HF. However, many of these patients are older and have multiple comorbidities that inc…
View article: Rates of Sudden Death After Myocardial Infarction—Insights From the VALIANT and PARADISE-MI Trials
Rates of Sudden Death After Myocardial Infarction—Insights From the VALIANT and PARADISE-MI Trials Open
Importance Sudden death is a leading cause of death after acute myocardial infarction (AMI). The Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) and Valsartan in Acut…
View article: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy Open
Background Prognostic markers and biological pathways linked to detrimental clinical outcomes in heart failure with preserved ejection fraction (HFpEF) remain incompletely defined. Methods and Results We measured serum levels of 4123 uniqu…
View article: Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF Open
BACKGROUND: A hypothetical concern has been raised that sacubitril/valsartan might cause cognitive impairment because neprilysin is one of several enzymes degrading amyloid-β peptides in the brain, some of which are neurotoxic and linked t…
View article: Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure Open
View article: High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT Open
View article: Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9—Pragmatic Research and Innovation through Multinational Experimentation
Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9—Pragmatic Research and Innovation through Multinational Experimentation Open
View article: Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial
Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial Open
View article: Clinical Heart fAilure Management Program: Changing the practice by partnering primary care and specialists (CHAMP-HF)
Clinical Heart fAilure Management Program: Changing the practice by partnering primary care and specialists (CHAMP-HF) Open
View article: Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan Open
Aims Red cell distribution width (RDW) is a strong prognostic marker in patients with heart failure (HF) and reduced ejection fraction and other conditions. However, very little is known about its prognostic significance in HF with preserv…
View article: Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction Open
Aims Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) are often treated with calcium channel blockers (CCBs), although the safety of CCBs in these patients is uncertain.…
View article: Frailty and outcomes in heart failure patients from high-, middle-, and low-income countries
Frailty and outcomes in heart failure patients from high-, middle-, and low-income countries Open
Background and Aims There is little information on the incremental prognostic importance of frailty beyond conventional prognostic variables in heart failure (HF) populations from different country income levels. Methods A total of 3429 ad…
View article: Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan
Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan Open
Aims Adrenomedullin is a vasodilatory peptide with a role in microcirculatory and endothelial homeostasis. Adrenomedullin is a substrate for neprilysin and may therefore play a role in beneficial effects of sacubitril/valsartan (Sac/Val) t…
View article: Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction
Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction Open
Aim Patients with heart failure (HF) often suffer from a range of comorbidities, which may affect their health status. The aim of this study was to assess the impact of different comorbidities on health status in patients with HF and reduc…
View article: Knowledge about self‐efficacy and outcomes in patients with heart failure and reduced ejection fraction
Knowledge about self‐efficacy and outcomes in patients with heart failure and reduced ejection fraction Open
Aim Although education in self‐management is thought to be an important aspect of the care of patients with heart failure, little is known about whether self‐rated knowledge of self‐management is associated with outcomes. The aim of this s…
View article: Stroke in patients with heart failure and reduced or preserved ejection fraction
Stroke in patients with heart failure and reduced or preserved ejection fraction Open
Aims Stroke is an important problem in patients with heart failure (HF), but the intersection between the two conditions is poorly studied across the range of ejection fraction. The prevalence of history of stroke and related outcomes were…
View article: Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation Open
BACKGROUND: The rate of stroke in patients with heart failure (HF) and preserved ejection fraction but without atrial fibrillation (AF), is uncertain as is whether it is possible to reliably predict the risk of stroke in these patients. ME…
View article: Incremental prognostic value of biomarkers in <scp>PARADIGM‐HF</scp>
Incremental prognostic value of biomarkers in <span>PARADIGM‐HF</span> Open
Aims It is uncertain how much candidate biomarkers improve risk prediction when added to comprehensive models including routinely collected clinical and laboratory variables in heart failure. Methods and results Aldosterone, cystatin C, hi…